Literature DB >> 15885735

Relationship of CD86 surface marker expression and cytotoxicity on dendritic cells exposed to chemical allergen.

Ben C Hulette1, Cindy A Ryan, Lucy A Gildea, G Frank Gerberick.   

Abstract

Human peripheral blood-derived dendritic cells (DC) respond to a variety of chemical allergens by up-regulating expression of the co-stimulatory molecule CD86. It has been postulated that this measure might provide the basis for an in vitro alternative approach for the identification of skin sensitizing chemicals. We recently reported that DC, exposed in culture to the highest non-cytotoxic concentrations of various chemical allergens, displayed marginal up-regulation of membrane CD86 expression; the interpretation being that such changes were insufficiently sensitive for the purposes of hazard identification. For the work presented here, immature DC were derived from human monocytes and treated with the chemical allergens 2,4-dinitrobenzenesulfonic acid (DNBS), nickel sulfate (NiSO4), p-phenylenediamine (PPD), Bandrowski's base (BB), hydroquinone (HQ) and propyl gallate (PG) for 48 h at concentrations which induced both no to slight to moderate cytotoxicity. For comparison, DC were treated with the irritants sodium dodecyl sulfate (SDS), benzoic acid (BA), and benzalkonium chloride (BZC) at concentrations resulting in comparable levels of cytotoxicity. CD86 expression, as measured by flow cytometry, was consistently up-regulated (ranging from 162 to 386% control) on DC treated with concentrations of chemical allergens that induced approximately 10-15% cytotoxicity. The irritants BA and BZC did not induce up-regulation of CD86 expression when tested at concentrations that induced similar levels of cytotoxicity. SDS, however, up-regulated CD86 expression to 125-138% of control in 2/4 preparations when tested at concentrations which induced similar toxicity. Our results confirm that chemical allergens up-regulate CD86 expression on blood-derived DC and illustrate further that up-regulation of CD86 surface marker expression is more robust when DC are treated with concentrations of chemical allergen that induce slight to moderate cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15885735     DOI: 10.1016/j.taap.2005.03.019

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  6 in total

Review 1.  Role of bioactivation in drug-induced hypersensitivity reactions.

Authors:  Joseph P Sanderson; Dean J Naisbitt; B Kevin Park
Journal:  AAPS J       Date:  2006-02-03       Impact factor: 4.009

2.  Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis.

Authors:  Philippe Azam; Ananthakrishnan Sankaranarayanan; Daniel Homerick; Stephen Griffey; Heike Wulff
Journal:  J Invest Dermatol       Date:  2007-02-01       Impact factor: 8.551

3.  A plasmacytoid dendritic cell (CD123+/CD11c-) based assay system to predict contact allergenicity of chemicals.

Authors:  Seyoum Ayehunie; Maureen Snell; Matthew Child; Mitchell Klausner
Journal:  Toxicology       Date:  2009-08-07       Impact factor: 4.221

Review 4.  [Sensitisation to p-Phenylenediamine. Effects of metabolism and individual susceptibility].

Authors:  R Brans; C Skazik; H F Merk; B Blömeke
Journal:  Hautarzt       Date:  2009-01       Impact factor: 0.751

5.  A new cytometry-based method reveals an accumulation of Nrf2 in dendritic cells exposed to two respiratory sensitizers.

Authors:  Adrien Audry; Julianne Mathiot; Samuel Muller; Amélie Coiscaud; Isabelle Langonné; Fabrice Battais; Brigitte Leininger; Isabelle Sponne
Journal:  Toxicol Res (Camb)       Date:  2021-11-26       Impact factor: 3.524

6.  Nature and kinetics of redox imbalance triggered by respiratory and skin chemical sensitizers on the human monocytic cell line THP-1.

Authors:  Isabel Ferreira; Ana Silva; João Demétrio Martins; Bruno Miguel Neves; Maria Teresa Cruz
Journal:  Redox Biol       Date:  2018-02-05       Impact factor: 11.799

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.